Search

Displaying results 4801 - 4810 of 10000 in total
  1. Drug

    Fosfructose

    go.drugbank.com/drugs/DB13863
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    LI-301

    go.drugbank.com/drugs/DB05509
    Experimental

    LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water. … This results in a slight dulling of sensation that can be used to treat premature ejaculation without interfering with normal sexual pleasure or orgasm.

  3. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. … It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.

  4. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

  5. Drug

    Difloxacin

    go.drugbank.com/drugs/DB11511
    ExperimentalVet approved

    However, it presents a reduced efficacy when compared to other fluoroquinolone antibacterials. … Difloxacin is a synthetic fluoroquinolone used in veterinary. As an antibacterial, it presents a broad bactericidal spectrum and its effects are dependent on its concentration.

  6. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  7. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. … Therapeutic options to improve exercise performance in these patients are limited

  8. Drug

    Lesopitron

    go.drugbank.com/drugs/DB04970
    Experimental

    Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.

  9. Drug

    Carotuximab

    go.drugbank.com/drugs/DB06322
    Investigational

  10. Drug

    Fentonium

    go.drugbank.com/drugs/DB08978
    ApprovedWithdrawn

    Fentonium is an atropine derivative.